- 全部删除
- 您的购物车当前为空
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 858 | 5日内发货 | |
25 mg | ¥ 5,850 | 1-2周 | |
50 mg | ¥ 7,610 | 1-2周 | |
100 mg | ¥ 11,800 | 1-2周 |
产品描述 | Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. Ruboxistaurin inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. |
靶点活性 | PKCγ:300 nM, PKCβI:4.7 nM, PKCη:52 nM, PKCε:600 nM, PKCδ:250 nM, PKCα:360 nM, PKCβII:5.9 nM |
别名 | LY-333531 Mesylate, LY-333531, LY333531, LY 333531 |
分子量 | 564.65 |
分子式 | C29H32N4O6S |
CAS No. | 192050-59-2 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容